Rinofima: una revisión de la literatura

Jorge Alberto Espinosa Reyes, Diana Patricia Parra Valencia

Resumen


El rinofima, a pesar de no ser una entidad común, sí es una patología que altera en forma importante la estética facial del individuo; por tal razón, su entendimiento, adecuado diagnóstico y terapia precisa son de gran relevancia para lograr la mejor recuperación posible. Entre las opciones de manejo existen múltiples herramientas, que van desde la prevención hasta procedimientos quirúrgicos agresivos. A pesar de lo anterior, los pacientes con rosácea, condición patológica inicial, avanzan por los diferentes estadios de la evolución de la enfermedad sin tratamiento médico adecuado, y terminan en el rinofima, condición final del proceso patológico. El objetivo de este artículo fue realizar una revisión de la literatura actual del tema..

Palabras clave


rinofima; rosácea; deformidad nasal.

Texto completo:

PDF

Referencias


Cello J, Hernández D. Rinofima. Tratamiento quirúrgico con el uso de radiofrecuencia. Cir Plast, 2007; 17 (3):176-180.

Winston C, Crabtree. Rhinophyma. California and Western Medicine, 1936; 45: 485-487.

Sams, Wiley M. Diseases of the skin. Arch Dermat and Syph, 1936, 26: 836-841.

Rohrich RJ, Griffin JR, Adams WP Jr. Rhinophyma: review and update. Plast Reconstr Surg, 2002; 110: 860-870.

Gil M, Boixeda J. Rosácea: revisión y nuevas alternativas terapéuticas. Semergen, 2011; 37 (2): 83-86.

Webster G. Rosacea. Med Clin N Am, 2009; 93: 1183-1194.

Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol, 1989; 69: 419-23.

Katz AM. Rosacea: epidemiology and pathogenesis. J Cut Med Surg, 1998; 2 (suppl. 4): 4-9.

Berstein JE, Soltani K. Alcohol - induced rosacea rubefaction blocked by naloxone. Br J Dermatol, 1982; 107: 59-62.

Orjuela P, Mendoza N. Rosácea. Centro Dermatológico Federico Lleras Acosta, 1998.

Aaron F, Cohen. Diagnosis and treatment of Rosacea. J Am Board Fam Pract, 2002; 15: 214-7.

Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol, 1969; 100: 686-92.

Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. Am J Gastroenterol, 1994; 89: 1603-4.

Utas S, Ozbakir O, Turasan A, et al. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol, 1999; 40: 433-5.

Hirschman JV. Does Helicobacter pylori have a role in the pathogenesis of rosacea? J Am Acad Dermatol, 2000; 42: 537-39.

Bamford JT, Tilden R, Blankush J, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol, 1999; 135: 659-63.

Goldman D. Tacrolimus ointment for the treatment of steroid induced rosacea, a preliminary report. J Am Acad Dermatol, 2001; 44: 995-9.

Bernard LA, Cunningham BB, Al-Suwaidan S, Friedlander SF, Eichenfield LF. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol, 2003; 139 (2): 229-231.

Jaramillo MJ, Stewart KJ, Kolhe PS. Phenytoin induced rhinophyma treated by excision and full thickness skin grafting. Br J Plast Surg, 2000; 53: 521-523.

Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol, 1998; 37: 421-5.

Roihu T, Kariniemi AL. Demodex mites in rosacea. J Cutan Pathol, 1998; 25: 550-2.

Zuber TJ. Rosacea. Dermatology. Prim Care, 2000; 27: 309-18.

Aloi F, Tomasini C, Soro E, Pippione M. The clinic pathologic spectrum of rhinophyma. J Am Acad Dermatol, 2000; 42 (3): 468-472.

Powell FC. Rosacea. N Engl J Med, 2005; 352 (8): 793-803.

Wilkin JK. Rosacea [review]. Int J Dermatol, 1983; 22: 393-400.

Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol, 1994; 130: 359-62.

Thiboutout D. Acne and rosacea. Dermatol Clin, 2000; 18: 63-71.

Ryan TJ. Structure and function of lymphatics. J Invest Dermatol, 1989; 93: 18s-24s.

Wilkin J, Detmar M, Drake L, et al. Standard classification of rosacea. J Am Acad Dermatol, 2002; 46.

Kligman AM. Ocular rosacea. Current concepts and therapy. Arch Dermatol, 1997; 133: 89-90.

Stone DU, Chodosh J. Ocular rosacea an update on pathogenesis and therapy. Curr Opin Ophthalmol, 2004; 15: 499-502.

Murray AH. Differential diagnosis of a red face. J Cutan Med Surg, 1998; 2 (Suppl 4): 11-5.

Freeman BS. Reconstructive rhinoplasty for rhinophyma. Plast Reconstr Surg, 1970; 46: 265-70.

Wei Lim S, Bekhor P. Rhinophyma: Carbon dioxide laser with computerized scanner is still an outstanding treatment. Australasian Journal of Dermatology, 2009; 50: 289-295.

Serrano C, Serrano S. Indicaciones actuales de la dermoabrasión. Cir Dermt, 2008; 23 (9): 514-8.

Seelig, MG. Surgical Clinics of North America, 5:1385.

New, Gordon: Surgical Clinics of North America, 1: 1395.

Del Rosso JQ. Systemic therapy for rosacea, focus on oral antibiotictherapy and safety. Cutis, 2000; 66: 7-13.

Wilkin JK. Use of topical products for maintaining remission in rosacea. Arch Dermatol, 1999; 135: 79-82.

Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis, 1998; 61: 44-7.

Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol, 1998; 134: 679-83.

Wereide K. Long term treatment of rosacea with oral tetracycline. Acta Derm Venereol, 1969; 49: 176-9.

Bikowski JB. Treatment of rosacea with doxycycline monohydrate. Cutis, 2000; 66: 149-52.

Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol, 1999; 40 (6 Pt 1): 961-5.

Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol, 2004; 43 (2): 151-154.

Hoting E, Paul E, Plewing G. Treatment of rosacea with isotretinoin. Int J Dermatol, 1986; 25: 660-3.

Carlin RB, Carlin CS. Topical vitamin C preparation reduces erythema of rosacea. Cosmetic Dermatol, 2001; Feb: 35-8.

Bogetti P, Boltri M, Spagnoli G, Dolcet M. Surgical treatment of rhinophyma: a comparison of techniques. Aesthetic Plast Surg., 2002; 26: 57-60.

Brightman L, Brauer J. Ablative and Fractional Ablative Lasers. Dermatol Clin, 2009; 27: 479-489.

Hsu CK, Lee JY, Wong TW. Good cosmesis of a large rhinophyma after carbon dioxide laser treatment. J Dermatol, 2006; 33: 227-9.

Simo R, Sharma VL. Treatment of rhinophyma with carbon dioxide laser. J Laryngol Otol, 1996; 110: 841-6.

El-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc, 1991; 66: 899-905.

Neuhaus IM, Zane LT, Tope WD. Comparative Efficacy of Nonpurpuragenic Pulsed Dye Laser and Intense Pulsed Light for erithematotelangiectatic Rosacea. Dermatol Surg, 2009; 35:920-8.

West TB, Alster TS. Comparison of the long pulse dye (590595 nm) and KTP (532 nm) lasers in the treatment of facial and leg telangiectasias. Derm Surg, 1998; 24: 510-2.

Patrick KY, Milind D, Francis CP. The gold standard for decortication of rhinophyma: combined erbium-YAG/CO2 Laser. Aesth Plast Surg, 2004; 28: 456-460.

Tanzi EL, Alster TS. Single-pass carbon dioxide versus multiple-pass Er: YAG laser skin resurfacing: a comparison of postoperative wound healing and side-effect rates. Dermatol Surg, 2003; 29: 80-4.

Orenstein A, Haik J, Tamir J, Winkler E, Frand J, Zilinsky I, Kaplan H. Treatment of rhinophyma with Er: YAG laser. Lasers Surg Med, 2001; 29: 230-5.

Greenbaum SS, Krull EA, Watnick K. Comparison of CO2 laser and electrosurgery in the treatment of rhinophyma. J Am Acad Dermatol, 1988; 18: 363-8.

Aferzon M, Millman B. Excision of rhinophyma with high frequency electro-surgery. Dermatol Surg, 2002; 28: 735-8.


Enlaces de Referencia

  • Por el momento, no existen enlaces de referencia